Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease
10.3760/cma.j.cn501113-20240226-00096
- VernacularTitle:代谢功能障碍相关脂肪性肝病新药临床试验现状和挑战
- Author:
Xin LUO
1
;
Lungen LU
;
Yimin MAO
Author Information
1. 上海交通大学医学院附属第一人民医院消化内科，上海 200080
- Keywords:
Fatty liver;
Metabolic dysfunction associated fatty liver disease?(MASLD);
Drug targets;
Clinical trials;
Research progress
- From:
Chinese Journal of Hepatology
2024;32(4):300-302
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic dysfunction-associated fatty liver disease (MASLD) is a major public health problem that seriously affects human health. At present, some good progress has been made in the research and development of new drugs for MASLD, but there is still great space for exploration. This paper summarizes and analyzes the reasons in the current clinical status and challenges for the research and development of new drugs for MASLD.
